发布求助
文献互助 智能选刊 最新文献

Trends in cancer最新文献

筛选
英文 中文
CD4+ T cells in antitumor immunity. 抗肿瘤免疫中的 CD4+ T 细胞。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2024-10-01 Epub Date: 2024-09-05 DOI: 10.1016/j.trecan.2024.07.009
Elena Montauti, David Y Oh, Lawrence Fong
{"title":"CD4<sup>+</sup> T cells in antitumor immunity.","authors":"Elena Montauti, David Y Oh, Lawrence Fong","doi":"10.1016/j.trecan.2024.07.009","DOIUrl":"10.1016/j.trecan.2024.07.009","url":null,"abstract":"<p><p>Advances in cancer immunotherapy have transformed cancer care and realized unprecedented responses in many patients. The growing arsenal of novel therapeutics - including immune checkpoint inhibition (ICI), adoptive T cell therapies (ACTs), and cancer vaccines - reflects the success of cancer immunotherapy. The therapeutic benefits of these treatment modalities are generally attributed to the enhanced quantity and quality of antitumor CD8<sup>+</sup> T cell responses. Nevertheless, CD4<sup>+</sup> T cells are now recognized to play key roles in both the priming and effector phases of the antitumor immune response. In addition to providing T cell help through co-stimulation and cytokine production, CD4<sup>+</sup> T cells can also possess cytotoxicity either directly on MHC class II-expressing tumor cells or to other cells within the tumor microenvironment (TME). The presence of specific populations of CD4<sup>+</sup> T cells, and their intrinsic plasticity, within the TME can represent an important determinant of clinical response to immune checkpoint inhibitors, vaccines, and chimeric antigen receptor (CAR) T cell therapies. Understanding how the antitumor functions of specific CD4<sup>+</sup> T cell types are induced while limiting their protumorigenic attributes will enable more successful immunotherapies.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"969-985"},"PeriodicalIF":14.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464182/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142146404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunomodulation by endothelial cells: prospects for cancer therapy 内皮细胞的免疫调节作用：癌症治疗的前景
IF 18.4 1区 医学
Trends in cancer Pub Date : 2024-09-16 DOI: 10.1016/j.trecan.2024.08.002
Halima Alnaqbi, Lisa M. Becker, Mira Mousa, Fatima Alshamsi, Sarah K. Azzam, Besa Emini Veseli, Lauren A. Hymel, Khalood Alhosani, Marwa Alhusain, Massimiliano Mazzone, Habiba Alsafar, Peter Carmeliet
{"title":"Immunomodulation by endothelial cells: prospects for cancer therapy","authors":"Halima Alnaqbi, Lisa M. Becker, Mira Mousa, Fatima Alshamsi, Sarah K. Azzam, Besa Emini Veseli, Lauren A. Hymel, Khalood Alhosani, Marwa Alhusain, Massimiliano Mazzone, Habiba Alsafar, Peter Carmeliet","doi":"10.1016/j.trecan.2024.08.002","DOIUrl":"https://doi.org/10.1016/j.trecan.2024.08.002","url":null,"abstract":"<p>Growing evidence highlights the importance of tumor endothelial cells (TECs) in the tumor microenvironment (TME) for promoting tumor growth and evading immune responses. Immunomodulatory endothelial cells (IMECs) represent a distinct plastic phenotype of ECs that exerts the ability to modulate immunity in health and disease. This review discusses our current understanding of IMECs in cancer biology, scrutinizing insights from single-cell reports to compare their characteristics and function dynamics across diverse tumor types, conditions, and species. We investigate possible implications of exploiting IMECs in the context of cancer treatment, particularly examining their influence on the efficacy of existing therapies and the potential to leverage them as targets in optimizing immunotherapeutic strategies.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":"17 1","pages":""},"PeriodicalIF":18.4,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142260216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metabolism and epigenetics: drivers of tumor cell plasticity and treatment outcomes 代谢和表观遗传学：肿瘤细胞可塑性和治疗效果的驱动因素
IF 18.4 1区 医学
Trends in cancer Pub Date : 2024-09-14 DOI: 10.1016/j.trecan.2024.08.005
Benjamin N. Gantner, Flavio R. Palma, Madhura R. Pandkar, Marcelo J. Sakiyama, Daniel Arango, Gina M. DeNicola, Ana P. Gomes, Marcelo G. Bonini
{"title":"Metabolism and epigenetics: drivers of tumor cell plasticity and treatment outcomes","authors":"Benjamin N. Gantner, Flavio R. Palma, Madhura R. Pandkar, Marcelo J. Sakiyama, Daniel Arango, Gina M. DeNicola, Ana P. Gomes, Marcelo G. Bonini","doi":"10.1016/j.trecan.2024.08.005","DOIUrl":"https://doi.org/10.1016/j.trecan.2024.08.005","url":null,"abstract":"<p>Emerging evidence indicates that metabolism not only is a source of energy and biomaterials for cell division but also acts as a driver of cancer cell plasticity and treatment resistance. This is because metabolic changes lead to remodeling of chromatin and reprogramming of gene expression patterns, furthering tumor cell phenotypic transitions. Therefore, the crosstalk between metabolism and epigenetics seems to hold immense potential for the discovery of novel therapeutic targets for various aggressive tumors. Here, we highlight recent discoveries supporting the concept that the cooperation between metabolism and epigenetics enables cancer to overcome mounting treatment-induced pressures. We discuss how specific metabolites contribute to cancer cell resilience and provide perspective on how simultaneously targeting these key forces could produce synergistic therapeutic effects to improve treatment outcomes.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":"26 1","pages":""},"PeriodicalIF":18.4,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142260218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Scaling data toward pan-cancer foundation models 扩大数据规模，建立泛癌症基础模型
IF 18.4 1区 医学
Trends in cancer Pub Date : 2024-09-11 DOI: 10.1016/j.trecan.2024.08.008
Nadieh Khalili, Francesco Ciompi
{"title":"Scaling data toward pan-cancer foundation models","authors":"Nadieh Khalili, Francesco Ciompi","doi":"10.1016/j.trecan.2024.08.008","DOIUrl":"https://doi.org/10.1016/j.trecan.2024.08.008","url":null,"abstract":"<p>Recent advances in artificial intelligence (AI) have revolutionized computational pathology (CPath), particularly through deep learning (DL) and neural networks (NNs). In a recent study, <span><span>Vorontsov <em>et al.</em></span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span> introduced Virchow, a new foundation model (FM) for CPath, which has shown promising results in cancer detection and biomarker prediction.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":"6 1","pages":""},"PeriodicalIF":18.4,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142206022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Environmental pollutants and bad bugs work hand in glove 环境污染物和坏虫子狼狈为奸
IF 18.4 1区 医学
Trends in cancer Pub Date : 2024-09-10 DOI: 10.1016/j.trecan.2024.08.007
Dingjiacheng Jia, Shujie Chen
{"title":"Environmental pollutants and bad bugs work hand in glove","authors":"Dingjiacheng Jia, Shujie Chen","doi":"10.1016/j.trecan.2024.08.007","DOIUrl":"https://doi.org/10.1016/j.trecan.2024.08.007","url":null,"abstract":"<p>‘Bad bacteria’ could alter the toxicokinetics of environmental pollutants, thereby exacerbating chemically induced tumorigenesis. Recently, <span><span>Roje <em>et al.</em></span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span> reported that specific gut microbiota can metabolize nitrosamine compounds to a toxic oxidation product, aggravating bladder cancer development and progression. These findings have important implications for tumor intervention through the gut microbiota.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":"15 1","pages":""},"PeriodicalIF":18.4,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142206023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advisory Board and Contents 咨询委员会和内容
IF 18.4 1区 医学
Trends in cancer Pub Date : 2024-09-10 DOI: 10.1016/s2405-8033(24)00176-6
{"title":"Advisory Board and Contents","authors":"","doi":"10.1016/s2405-8033(24)00176-6","DOIUrl":"https://doi.org/10.1016/s2405-8033(24)00176-6","url":null,"abstract":"No Abstract","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":"8 1","pages":""},"PeriodicalIF":18.4,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142206019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Subscription & copyright page 订阅和版权页面
IF 18.4 1区 医学
Trends in cancer Pub Date : 2024-09-10 DOI: 10.1016/s2405-8033(24)00179-1
{"title":"Subscription & copyright page","authors":"","doi":"10.1016/s2405-8033(24)00179-1","DOIUrl":"https://doi.org/10.1016/s2405-8033(24)00179-1","url":null,"abstract":"No Abstract","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":"45 1","pages":""},"PeriodicalIF":18.4,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142206018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transcriptomic subtyping of gastrointestinal malignancies. 胃肠道恶性肿瘤的转录组亚型。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2024-09-01 Epub Date: 2024-07-16 DOI: 10.1016/j.trecan.2024.06.007
Tim R de Back, Sander R van Hooff, Dirkje W Sommeijer, Louis Vermeulen
{"title":"Transcriptomic subtyping of gastrointestinal malignancies.","authors":"Tim R de Back, Sander R van Hooff, Dirkje W Sommeijer, Louis Vermeulen","doi":"10.1016/j.trecan.2024.06.007","DOIUrl":"10.1016/j.trecan.2024.06.007","url":null,"abstract":"<p><p>Gastrointestinal (GI) cancers are highly heterogeneous at multiple levels. Tumor heterogeneity can be captured by molecular profiling, such as genetic, epigenetic, proteomic, and transcriptomic classification. Transcriptomic subtyping has the advantage of combining genetic and epigenetic information, cancer cell-intrinsic properties, and the tumor microenvironment (TME). Unsupervised transcriptomic subtyping systems of different GI malignancies have gained interest because they reveal shared biological features across cancers and bear prognostic and predictive value. Importantly, transcriptomic subtypes accurately reflect complex phenotypic states varying not only per tumor region, but also throughout disease progression, with consequences for clinical management. Here, we discuss methodologies of transcriptomic subtyping, proposed taxonomies for GI malignancies, and the challenges posed to clinical implementation, highlighting opportunities for future transcriptomic profiling efforts to optimize clinical impact.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"842-856"},"PeriodicalIF":14.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141634585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Precision oncology: current and future platforms for treatment selection. 精准肿瘤学：当前和未来的治疗选择平台。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2024-09-01 Epub Date: 2024-07-19 DOI: 10.1016/j.trecan.2024.06.009
Xinran Tang, Michael F Berger, David B Solit
{"title":"Precision oncology: current and future platforms for treatment selection.","authors":"Xinran Tang, Michael F Berger, David B Solit","doi":"10.1016/j.trecan.2024.06.009","DOIUrl":"10.1016/j.trecan.2024.06.009","url":null,"abstract":"<p><p>Genomic profiling of hundreds of cancer-associated genes is now a component of routine cancer care. DNA sequencing can identify mutations, mutational signatures, and structural alterations predictive of therapy response and assess for heritable cancer risk, but it has been less useful for identifying predictive biomarkers of sensitivity to cytotoxic chemotherapies, antibody drug conjugates, and immunotherapies. The clinical adoption of molecular profiling platforms such as RNA sequencing better suited to identifying those patients most likely to respond to immunotherapies and drug combinations will be critical to expanding the benefits of precision oncology. This review discusses the potential advantages of innovative molecular and functional profiling platforms designed to replace or complement targeted DNA sequencing and the major hurdles to their clinical adoption.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"781-791"},"PeriodicalIF":14.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141727826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PARPi, BRCA, and gaps: controversies and future research. PARPi、BRCA 和差距：争议与未来研究。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2024-09-01 DOI: 10.1016/j.trecan.2024.06.008
Diego Dibitetto, Carmen A Widmer, Sven Rottenberg
{"title":"PARPi, BRCA, and gaps: controversies and future research.","authors":"Diego Dibitetto, Carmen A Widmer, Sven Rottenberg","doi":"10.1016/j.trecan.2024.06.008","DOIUrl":"10.1016/j.trecan.2024.06.008","url":null,"abstract":"<p><p>In recent years, various poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) have been approved for the treatment of several cancers to target the vulnerability of homologous recombination (HR) deficiency (e.g., due to BRCA1/2 dysfunction). In this review we analyze the ongoing debates and recent breakthroughs in the use of PARPis for BRCA1/2-deficient cancers, juxtaposing the 'double-strand break (DSB)' and 'single-stranded DNA (ssDNA) gap' models of synthetic lethality induced by PARPis. We spotlight the complexity of this interaction, highlighting emerging research on the role of DNA polymerase theta (POLθ) and ssDNA gaps in shaping therapy responses. We scrutinize the clinical ramifications of these findings, especially concerning PARPi efficacy and resistance mechanisms, underscoring the heterogeneity of BRCA-mutated tumors and the urgent need for advanced research to bridge the gap between laboratory models and patient outcomes.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"857-869"},"PeriodicalIF":14.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141617173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信